Patents Assigned to Threshold Pharmaceuticals, Inc.
  • Phosphoramidate alkylator prodrugs
    Patent number: 8003625
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 23, 2011
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Glufosfamide combination therapy
    Publication number: 20110182909
    Abstract: Glufosfamide administered in combination with other chemotherapeutic agents is useful in cancer treatment.
    Type: Application
    Filed: December 22, 2005
    Publication date: July 28, 2011
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventor: George Tidmarsh
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS FOR THE TREATMENT OF CANCER
    Publication number: 20100183742
    Abstract: Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.
    Type: Application
    Filed: December 21, 2007
    Publication date: July 22, 2010
    Applicant: Threshold Pharmaceuticals, Inc
    Inventors: Steve Ammons, Jian-Xin Duan, Donald Jung, Mark Matteucci
  • GLUFOSFAMIDE COMBINATION THERAPY
    Publication number: 20100104549
    Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.
    Type: Application
    Filed: April 7, 2008
    Publication date: April 29, 2010
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Damian Handisides, Stewart Kroll, Jian-Xin Duan, Harold E. Selick
  • Method for determining susceptibility of tumor to treatment with anti-neoplastic agent
    Patent number: 7560230
    Abstract: The level of one or more glucose transporters in a sample containing cancer cells is measured and compared to a reference value to determine whether the cancer is susceptible to treatment with an anti-cancer agent comprising glucose or glucose analog that is transported into the cancer by a glucose transporter.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: July 14, 2009
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventor: George Tidmarsh
  • Compositions and methods for treating cancer
    Patent number: 7550496
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: June 23, 2009
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
    Publication number: 20090042820
    Abstract: Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed.
    Type: Application
    Filed: November 17, 2005
    Publication date: February 12, 2009
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Xiaohong Cai
  • Analytical Methods For 2-Deoxy-D-Glucose
    Publication number: 20080276694
    Abstract: 2-Deoxy-2-D-glucose (2-DG) concentration and purity can be measured in a sample of crystalline or liquid by HPLC with accuracy and precision suitable for analysis of active pharmaceutical ingredient and drug product.
    Type: Application
    Filed: June 22, 2005
    Publication date: November 13, 2008
    Applicant: Threshold Pharmaceutical, Inc.
    Inventor: Michael Li
  • Topoisomerase Inhibitors and Prodrugs
    Publication number: 20080214576
    Abstract: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.
    Type: Application
    Filed: November 27, 2005
    Publication date: September 4, 2008
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Photon Rao
  • Hypoxia-Activated Anti-Cancer Agents
    Publication number: 20080132458
    Abstract: Prodrugs of cyclic anthracyclin toxins comprising a hypoxia-activated trigger and are disclosed. In addition, methods of treating cancer using the compounds of the invention are disclosed.
    Type: Application
    Filed: March 10, 2005
    Publication date: June 5, 2008
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan
  • Anthracycline analogs
    Publication number: 20070060534
    Abstract: Anthracycline analogs and their bioconjugates are useful as anticancer agents.
    Type: Application
    Filed: June 30, 2006
    Publication date: March 15, 2007
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Xiaohong Cai
  • Lonidamine analogs
    Publication number: 20070043057
    Abstract: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.
    Type: Application
    Filed: February 1, 2006
    Publication date: February 22, 2007
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Lonidamine analogs
    Publication number: 20070015771
    Abstract: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.
    Type: Application
    Filed: February 8, 2006
    Publication date: January 18, 2007
    Applicant: Threshold pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Compositions and methods for treating cancer
    Publication number: 20060258656
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: March 29, 2004
    Publication date: November 16, 2006
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Treatment of benign prostatic hyperplasia using energolytic agents
    Publication number: 20060172953
    Abstract: The invention provides a method for treatment or prophylaxis of benign prostatic hyperplasia by administration of an agent that interferes with energy metabolism, particularly the production of ATP and NADH/NADPH, in prostate epithelial cells.
    Type: Application
    Filed: January 16, 2004
    Publication date: August 3, 2006
    Applicant: Threshold Pharmaceuticals Inc.
    Inventors: George Tidmarsh, Harold Selick
  • Methods for cancer imaging
    Publication number: 20060165597
    Abstract: Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.
    Type: Application
    Filed: November 30, 2005
    Publication date: July 27, 2006
    Applicant: Threshold Pharmaceutical, Inc.
    Inventors: George Tidmarsh, Mark Matteucci
  • Compositions and methods for treating cancer
    Publication number: 20060142207
    Abstract: Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.
    Type: Application
    Filed: December 1, 2005
    Publication date: June 29, 2006
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: George Tidmarsh, Mark Matteuccii, Photon Rao
  • Compositions and methods for treating cancer
    Patent number: 7001888
    Abstract: Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: February 21, 2006
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: George Tidmarsh, Mark Matteucci, Photon Rao
  • Methods for cancer imaging
    Patent number: 6989140
    Abstract: Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: January 24, 2006
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: George Tidmarsh, Mark Matteucci
  • Treatment of benign prostatic hyperplasia
    Patent number: 6989400
    Abstract: A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidamine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: January 24, 2006
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventor: George Tidmarsh